Managing central nervous system spread of lung cancer: the state of the art

DCC Tsui, DR Camidge, CG Rusthoven - Journal of Clinical Oncology, 2022 - ascopubs.org
lung cancer care. In this article, we review the management and recent advances in the
treatment of lung cancer with spread to the CNS… Discordant CNS and extra CNS responses were …

CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives

LA Berger, H Riesenberg, C Bokemeyer… - Lung Cancer, 2013 - Elsevier
… Remarkably, in this population, which was probably enriched for patients with activating
EGFR mutations (Asian ethnicity, mostly never-smokers, adenocarcinomas), the CNS response

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non–Small-Cell Lung Cancer

SM Gadgeel, AT Shaw, R Govindan… - Journal of Clinical …, 2016 - ascopubs.org
CNS DCR (CDCR) was defined as the percentage of patients who had a best overall CNS
response … first observation of a CNS response until the first observation of CNS progression or …

An update on the treatment of CNS metastases in small cell lung cancer

WA Castrucci, JPS Knisely - The Cancer Journal, 2008 - journals.lww.com
… Prophylactic cranial irradiation is indicated following complete response to induction
therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom …

[HTML][HTML] Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against …

P Economopoulou, G Mountzios - Translational lung cancer …, 2016 - ncbi.nlm.nih.gov
… chemotherapy for BM, with intracranial response rates (RR) comparable to systemic RR,
warranting further research on the role of chemotherapy in CNS disease from NSCLC (7-12). …

[HTML][HTML] Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX …

S Gadgeel, S Peters, T Mok, AT Shaw, DW Kim, SI Ou… - Annals of oncology, 2018 - Elsevier
… cell lung cancer (NSCLC) is characterized by a high prevalence of central nervous system
(CNS… Although CNS responses are well documented with ceritinib, these differences, together …

CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)

YL Wu, MJ Ahn, MC Garassino, JY Han… - Journal of Clinical …, 2018 - ascopubs.org
… was CNS objective response rate (ORR). … CNS tumor shrinkage. Additional analyses
included the effect of prior radiotherapy on CNS response and a competing risk analysis of CNS

[HTML][HTML] Advances in the management of central nervous system metastases in non-small cell lung cancer

A D'Aiello, E Miao, H Cheng - Cancers, 2023 - mdpi.com
CNS response lasting in the range of 9–12 months only (Table 1). In addition, while there
is limited data on toxicities from combined approaches of SRS and TKIs, there is the potential …

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …

S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
central nervous system (CNS) and elicit responses in patients with brain metastases (BM)
from non–small cell lung cancer (… impact on the development and control of CNS metastases. …

Pulsed dosing of erlotinib for central nervous system (CNS) progression in EGFR-mutant non-small cell lung cancer (NSCLC).

DM Jackman, SL Mach, JC Heng, MS Rabin… - 2013 - ascopubs.org
… The overall CNS response rate was 10% (1/10); 2 others achieved CNS stability. Median
overall survival was 1.7 months (range 0.6 – 7.0). There was no clear correlation between …